EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Bruton’s tyrosine kinase inhibitors in primary immune thrombocytopenia: pathophysiology and clinical evidence

Tomás José González-López, Rick Kapur

Blood Vessels, Thrombosis & Hemostasis · 2026-11 · 3 (4) · 100223

DOI: 10.1016/j.bvth.2026.100223 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Blood Vessels, Thrombosis & Hemostasis, 2026-11. Verfasst von Tomás José González-López und 1 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Hospital Universitario de Burgos, Burgos, Spain. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Hematology Department, Hospital Universitario de Burgos, Burgos, Spain.
  • Department of Research, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands.
  • Landsteiner Laboratory, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.

Zitieren

APA

González-López, T. J., & Kapur, R. (2026). Bruton’s tyrosine kinase inhibitors in primary immune thrombocytopenia: pathophysiology and clinical evidence. Blood Vessels, Thrombosis & Hemostasis, 3(4), 100223. https://doi.org/10.1016/j.bvth.2026.100223

Vancouver

González-López TJ, Kapur R. Bruton’s tyrosine kinase inhibitors in primary immune thrombocytopenia: pathophysiology and clinical evidence. Blood Vessels, Thrombosis & Hemostasis. 2026;3(4):100223. doi:10.1016/j.bvth.2026.100223

BibTeX
@article{GonzlezLpez2026,
  author = {González-López, Tomás José and Kapur, Rick},
  title = {Bruton’s tyrosine kinase inhibitors in primary immune thrombocytopenia: pathophysiology and clinical evidence},
  journal = {Blood Vessels, Thrombosis & Hemostasis},
  year = {2026},
  volume = {3},
  number = {4},
  pages = {100223},
  doi = {10.1016/j.bvth.2026.100223}
}
Kostenlos starten →